Loading organizations...
AbolerIS Pharma is a preclinical-stage biotechnology company based in Gosselies, Belgium, that develops novel immunomodulators to treat severe autoimmune diseases and prevent organ transplant rejection. The enterprise utilizes proprietary monoclonal antibodies targeting CD45RC and regulatory T cell therapies to induce immune tolerance while preserving essential immune responses. Operating within the immunology sector, the firm targets unmet medical needs in conditions such as rheumatoid arthritis, lupus, and multiple sclerosis across European and North American markets. The company has secured significant venture capital funding to advance its clinical trials, highlighted by a €27.3 million Series A financing round backed by prominent institutional investors including Newton Biocapital, SFPI-FPIM, and Sambrinvest. AbolerIS Pharma was originally founded in 2019 as a spin-off from the Center for Research in Transplantation and Translational Immunology by Carole Guillonneau, Ignacio Anegon, and François-Xavier Hubert.
AbolerIS Pharma has raised $29.0M across 1 funding round.
AbolerIS Pharma has raised $29.0M in total across 1 funding round.
AbolerIS Pharma has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series A in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $29M Series A | Caixa Capital Risc | BioVentures Investors, Newton Biocapital, Sambrinvest, Sfpi Fpim, Sound Bioventures, Sudinvest, Turenne Capital, Wallonie Entreprendre | Announced |
AbolerIS Pharma is a Belgian biopharmaceutical company developing first-in-class monoclonal antibodies to restore immune system balance in chronic autoimmune and inflammatory diseases.[1][2][4] Its lead program, ABO21009—an anti-CD45RC antibody—targets pathogenic T and B cells while preserving useful immune responses, addressing high unmet needs in conditions like rheumatoid arthritis; the company has advanced to clinical-stage, with the first cohort dosed in a Phase 1 study.[1][2] Backed by investors like Sound Bioventures, AbolerIS focuses on inducing immune tolerance for inflammatory, autoimmune, and degenerative diseases, serving patients who lack effective treatments.[2][4]
AbolerIS Pharma was founded by three renowned scientists: Dr. Carole Guillonneau, Dr. Ignacio Anegon, and Dr. François-Xavier Hubert, leveraging their expertise in immunology and autoimmune disease research.[4] The idea emerged from their work on therapeutic targets for pathological immune responses, with Guillonneau inventing 19 related patents and coordinating discovery projects.[4] Early traction included pre-clinical development of immunomodulators for transplant rejection, graft-versus-host disease, and autoimmunity, culminating in a Series A financing and progression to clinical trials, including the April 2025 announcement from Gosselies, Belgium, and Nantes, France.[1][2][4]
AbolerIS rides the autoimmunity treatment wave, where immune tolerance therapies address limitations of existing drugs that broadly suppress immunity, risking infections.[1][2][4] Timing aligns with rising autoimmune disease prevalence and biotech momentum in precision immunomodulation, bolstered by events like the 2025 EULAR Congress.[1] Market forces favor it through investor interest (e.g., Sound Bioventures) and regulatory progress, positioning AbolerIS to influence the ecosystem by pioneering CD45RC-targeting for rheumatoid arthritis and beyond, potentially expanding to transplants and neurodegeneration.[2][4]
AbolerIS Pharma's Phase 1 momentum with ABO21009 signals a potential game-changer in autoimmunity, with upcoming data readouts and congress presentations shaping validation.[1][2] Trends like personalized immunomodulation and AI-driven target discovery will accelerate its pipeline, possibly leading to partnerships or Phase 2 trials by 2026. Its influence could grow by filling gaps in immune-balancing therapies, evolving from clinical-stage contender to key player in restoring immune control for millions. This positions AbolerIS as a precise innovator in a chaotic disease landscape.[1][4]
AbolerIS Pharma has raised $29.0M in total across 1 funding round.
AbolerIS Pharma's investors include Caixa Capital, BioVentures Investors, Newton Biocapital, Sambrinvest, SFPI-FPIM, Sound Bioventures, Sudinvest, Turenne Capital, Wallonie Entreprendre.
